1 / 1

Relugolix(MYFEMBREE)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Formulation:

TABLET

Validity period:

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

MYFEMBREE is a medication used to manage conditions such as heavy menstrual bleeding caused by uterine fibroids and moderate to severe pain associated with endometriosis in premenopausal women. It combines three active ingredients: relugolix, a GnRH receptor antagonist; estradiol, an estrogen; and norethindrone acetate, a progestin. MYFEMBREE reduces hormone levels to alleviate symptoms related to these conditions. However, due to potential risks such as bone loss, treatment should be limited to a period of 24 months.

The medication is available as a fixed-dose combination tablet, and it is crucial to follow the prescribed dosage and administration instructions, including excluding pregnancy before starting treatment. The use of MYFEMBREE can cause side effects, so monitoring and proper medical advice are important throughout treatment.

Generic name

Relugolix(MYFEMBREE)

English name

Relugolix

Alternative Names

MYFEMBREE

Drug prices

Indications

Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women

Management of moderate to severe pain associated with endometriosis in premenopausal women

Therapeutic Target

Gonadotropin-releasing hormone (GnRH) receptors, estrogen receptors, and progesterone receptors

Active Ingredients

Relugolix 40 mg (GnRH receptor antagonist) Estradiol 1 mg (estrogen) Norethindrone acetate 0.5 mg (progestin)

Dosage form

TABLET

specifications

Description

MYFEMBREE is a fixed-dose combination tablet containing relugolix (40 mg), a GnRH receptor antagonist, estradiol (1 mg), an estrogen, and norethindrone acetate (0.5 mg), a progestin. The tablets are light yellow to yellow, round, film-coated, and debossed with "MVT" on one side and "415" on the other side.

Dosage and Administration

Prior to Initiation:

Exclude pregnancy

Discontinue hormonal contraceptives

Recommended Dosage:

One tablet orally once daily at approximately the same time, with or without food

Start as early as possible after the onset of menses but no later than seven days after menses has started

Recommended total duration of treatment is 24 months

Missed Dose:

Take the missed dose as soon as possible the same day and resume regular dosing the next day at the usual time

Dosage Modification for Concomitant Use with P-gp Inhibitors:

Avoid concomitant use with oral P-gp inhibitors

If unavoidable, take MYFEMBREE first and separate dosing by at least 6 hours

CATEGORY NAVIGATION